A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
Status:
Not yet recruiting
Trial end date:
2025-10-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of aticaprant
administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake
inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all
participants with major depressive disorder (MDD).